Date: 2017-06-30

Type of information: Co-promotion agreement

Compound: Dysport® (abobotulinumtoxin A )

Company: Ipsen (France) Saol Therapeutics (USA - GA)

Therapeutic area: Neurological diseases - Neuromuscular diseases

Type agreement: co-promotion

Action mechanism: protein. Dysport® is an injectable form of botulinum toxin type A (BTX-A), which is isolated and purified from Clostridium BTX-A bacteria. It is supplied as a lyophilized powder. Dysport® was first registered for the treatment of blepharospasm and hemifacial spasm in the United Kingdom in 1990, and is licensed in 82 countries for various indications including: blepharospasm, adult upper and lower limb spasticity, hemifacial spasm, spasmodic torticollis (ST) (previously referred to as cervical dystonia), pediatric lower limb spasticity due to cerebral palsy (CP), axillary hyperhidrosis, and glabellar lines. Dysport® is approved for the treatment of upper limb spasticity and pediatric lower limb spasticity in many international markets, but not in the United States. Dysport® is also approved for the treatment of adult lower limb spasticity.

Disease: adult spasticity, pediatric lower limb spasticity


  • • On June 30, 2017, Ipsen announced that its US affiliate has entered into an exclusive, three-year agreement with Saol Therapeutics Inc. to promote Dysport® (abobotulinumtoxinA) for injection for approved therapeutic indications in adult spasticity and pediatric lower limb spasticity in the United States. Under the terms of the agreement, Saol’s sales force will promote Dysport® to healthcare professionals largely in the hospital setting beginning August 2017.
  • Ipsen will maintain its current number of sales representatives fully dedicated to Dysport® including all its therapeutic indications. Additional details of the agreement are not disclosed.

Financial terms:

Latest news:

Is general: Yes